FTC Loses K-Dur Antitrust Case; Failure To Consider Schering Patent Cited
Executive Summary
The Federal Trade Commission should consider the potential exclusionary scope of a brand-name drug company's patents when evaluating whether a settlement with a generic company is anticompetitive, a federal appeals court ruled March 8
You may also be interested in...
Reverse Payment Settlements Suffer Reversal Of Fortune At Third Circuit
FTC ends its losing streak on patent settlement suits as the Third Circuit says “rule of reason” rather than “scope of patent” analysis should be applied to brand/generic settlements; appeals court reinstates suit by direct purchasers challenging Schering’s payments to Upsher-Smith and ESI Lederle.
FTC Tries Again On K-Dur; Joins Pharmacies, DoJ In Appeal Of Reverse Settlement Case
Strength of patent is a focus of FTC's amicus brief; the Commission acknowledges that it has inappropriately ignored the issue in the past.
Brand/Generic Settlements Bill May Pass, But Industry Sees Room To Maneuver
Recently introduced House legislation, while prohibiting "reverse" payments by brand pharmaceutical companies to delay generic launches, would be far more palatable to industry than its Senate counterpart because it confines potential violations to the Federal Trade Commission Act, according to Pfizer Corporate Counsel Dara Diomande